Latest news with #epigenetics
Globe and Mail
2 days ago
- Business
- Globe and Mail
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes For Votes Withheld Percent For Percent Withheld Donald J. McCaffrey 144,544,411 5,161,746 96.55% 3.45% Kelly McNeill 144,898,132 4,808,025 96.79% 3.21% Siu Lun (Dicky) To 145,379,921 4,326,236 97.11% 2.89% Kenneth Zuerblis 145,121,418 4,584,739 96.94% 3.06% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 16, 2025 (the "Information Circular"). The Information Circular is available on SEDAR+ at and on the Resverlogix website at A webcast archive of the executive presentation portion of the Meeting will be available HERE. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions — altered by serious illnesses such as cardiovascular disease — back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Yahoo
2 days ago
- Business
- Yahoo
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes For Votes Withheld Percent For Percent Withheld Donald J. McCaffrey 144,544,411 5,161,746 96.55% 3.45% Kelly McNeill 144,898,132 4,808,025 96.79% 3.21% Siu Lun (Dicky) To 145,379,921 4,326,236 97.11% 2.89% Kenneth Zuerblis 145,121,418 4,584,739 96.94% 3.06% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 16, 2025 (the "Information Circular"). The Information Circular is available on SEDAR+ at and on the Resverlogix website at A webcast archive of the executive presentation portion of the Meeting will be available HERE. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions — altered by serious illnesses such as cardiovascular disease — back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor RelationsEmail: ir@ 403-254-9252 To view the source version of this press release, please visit Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
ABC News
5 days ago
- Health
- ABC News
Can 'biological clock' tests tell you anything worthwhile?
We all like to imagine we're ageing well. Now a simple blood or saliva test promises to tell us by measuring our "biological age". And then, as many have done, we can share how "young" we really are on social media, along with our secrets to success. While chronological age is how long you have been alive, measures of biological age aim to indicate how old your body actually is, purporting to measure "wear and tear" at a molecular level. The appeal of these tests is undeniable. Health-conscious consumers may see their results as reinforcing their anti-ageing efforts, or a way to show their journey to better health is paying off. But how good are these tests? Do they actually offer useful insights? Or are they just clever marketing dressed up to look like science? Over time, the chemical processes that allow our body to function, known as our "metabolic activity", lead to damage and a decline in the activity of our cells, tissues and organs. Biological age tests aim to capture some of these changes, offering a snapshot of how well, or how poorly, we are ageing on a cellular level. Our DNA is also affected by the ageing process. In particular, chemical tags (methyl groups) attach to our DNA and affect gene expression. These changes occur in predictable ways with age and environmental exposures, in a process called methylation. Research studies have used "epigenetic clocks", which measure the methylation of our genes, to estimate biological age. By analysing methylation levels at specific sites in the genome from participant samples, researchers apply predictive models to estimate the cumulative wear and tear on the body. Although the science is rapidly evolving, the evidence underpinning the use of epigenetic clocks to measure biological ageing in research studies is strong. Studies have shown epigenetic biological age estimation is a better predictor of the risk of death and ageing-related diseases than chronological age. Epigenetic clocks also have been found to correlate strongly with lifestyle and environmental exposures, such as smoking status and diet quality. In addition, they have been found to be able to predict the risk of conditions such as cardiovascular disease, which can lead to heart attacks and strokes. Taken together, a growing body of research indicates that at a population level, epigenetic clocks are robust measures of biological ageing and are strongly linked to the risk of disease and death. While these tests are valuable when studying populations in research settings, using epigenetic clocks to measure the biological age of individuals is a different matter and requires scrutiny. For testing at an individual level, perhaps the most important consideration is the "signal to noise ratio" (or precision) of these tests. This is the question of whether a single sample from an individual may yield widely differing results. A study from 2022 found samples deviated by up to nine years. So an identical sample from a 40-year-old may indicate a biological age of as low as 35 years (a cause for celebration) or as high as 44 years (a cause of anxiety). While there have been significant improvements in these tests over the years, there is considerable variability in the precision of these tests between commercial providers. So depending on who you send your sample to, your estimated biological age may vary considerably. Another limitation is there is currently no standardisation of methods for this testing. Commercial providers perform these tests in different ways and have different algorithms for estimating biological age from the data. As you would expect for commercial operators, providers don't disclose their methods. So it's difficult to compare companies and determine who provides the most accurate results — and what you're getting for your money. A third limitation is that while epigenetic clocks correlate well with ageing, they are simply a "proxy" and are not a diagnostic tool. In other words, they may provide a general indication of ageing at a cellular level. But they don't offer any specific insights about what the issue may be if someone is found to be "ageing faster" than they would like, or what they're doing right if they are "ageing well". So regardless of the result of your test, all you're likely to get from the commercial provider of an epigenetic test is generic advice about what the science says is healthy behaviour. While companies offering these tests may have good intentions, remember their ultimate goal is to sell you these tests and make a profit. And at a cost of around $500, they're not cheap. While the idea of using these tests as a personalised health tool has potential, it is clear that we are not there yet. For this to become a reality, tests will need to become more reproducible, standardised across providers, and validated through long-term studies that link changes in biological age to specific behaviours. So while one-off tests of biological age make for impressive social media posts, for most people they represent a significant cost and offer limited real value. The good news is we already know what we need to do to increase our chances of living longer and healthier lives. These include: We don't need to know our biological age in order to implement changes in our lives right now to improve our health. Hassan Vally is an associate professor of epidemiology at Deakin University. This piece first appeared on The Conversation.
News.com.au
11-06-2025
- Health
- News.com.au
‘More responsibility': Fertility expert's urgent warning to men
Fertility experts are warning that age and lifestyle choices are jeopardising Australian men's chances of becoming fathers. Male infertility accounts for one-third of fertility issues, yet many men don't adjust their habits ahead of conception. With the median age of Australian fathers now at 33.8 (compared to 29 years in 1977), there is an even greater need for men to transform their habits before trying to conceive. Emma Ebinger, National Scientific Director at Adora Fertility, says that it's time to reframe fertility as a shared responsibility, not just a women's issue. 'I think men sometimes don't stop to give enough thought about their role and what they could be doing to improve their chances of success,' she tells She notes that it can take around two and a half months for sperm to form in the body, and during that time, their quality can be influenced by factors such as smoking, drugs, diet, and alcohol. Vaping may also impair fertility – just as much as cigarettes can – with studies linking e-cigarettes to reduced sperm count, motility, and DNA integrity. 'All of these lifestyle and environmental effects are known as epigenetics as they can impact the sperm's DNA,' she says. 'The sperm contributes 50 per cent of the DNA to the developing foetus, which is the biological blueprint of the developing baby.' She advises men to also be aware of 'endocrine-disrupting chemicals' – found in plastics, solvents, paints, cosmetics, and textiles – which can negatively affect fertility by impacting hormones responsible for sperm production. 'It can be really hard to avoid these chemicals completely, but minimising the use of plastics in your daily life, such as not reheating food in takeaway containers or drinking from disposable water bottles, is advisable,' Ms Ebinger notes. Additionally, Ms Ebinger suggests limiting activities that excessively raise their surrounding temperature, such as very hot baths, spas, and sauna sessions. This is because male testicles are located outside the body as they require slightly cooler conditions for sperm production than body temperature. So, what can men do to enhance their fertility? Ms Ebinger emphasises that it is not a one-size-fits-all approach, but overall lifestyle changes are encouraged to ensure that a couple is in the best physical shape possible before having a baby. Cutting back on alcohol, avoiding smoking and recreational drugs, consuming whole foods, and engaging in regular exercise are all important components of the puzzle. Regarding when men should begin making these lifestyle changes prior to attempting conception, she says three months beforehand is a good guideline. 'It's a great time for them to have an overall health check-up with their GP as well and address any ongoing health concerns they may have,' she adds. 'There is some scientific evidence that taking antioxidant supplements may also help in ensuring the sperm is as healthy as possible, but these should be taken in conjunction with a healthy diet and lifestyle.' Karlee and Jason Sondergeld, from Townsville, struggled with infertility for two years before welcoming a baby via IVF in December 2023. The couple, both 30, were deeply committed to making positive lifestyle changes on their journey to conceive. 'We wanted to give ourselves the best possible chance to start a family,' they said. 'We started looking into the role that male fertility plays in conception, and we changed our diet, reducing stress, getting quality sleep, cutting back on alcohol, taking a good quality male fertility supplement, and just being more mindful of our overall health, which meant we had a lot more energy and a clearer headspace.' Leaning on each other for support was crucial during the oftentimes emotional process. 'For me as a male partner, I think there can be a feeling of helplessness, especially during the parts where most of the physical burden is on your partner,' Mr Sondergeld explained. 'But I tried my hardest to stay really involved, which helped me feel connected and supportive.' Following the birth of their baby Rylan, they credited the small changes they made that helped with fertility. 'Even if you're just starting to consider IVF or fertility support, taking steps towards a healthier lifestyle together can make a huge difference, both physically and mentally,' they advised. 'Be kind to yourselves and remember you're not failing, you're just taking a different path to parenthood. And the path is valid, still powerful, and still full of a lot of love.'
South China Morning Post
27-05-2025
- Science
- South China Morning Post
French Lamarckism beats Darwinism in China's groundbreaking study on evolution
In a fundamental challenge to more than a century of Darwinian dominance, Chinese scientists have revived a long-dismissed evolutionary theory by proving that acquired traits can shape heredity – no DNA changes required. According to a landmark study published in the esteemed scientific journal Cell, rice plants subjected to cold stress passed on an adaptive tolerance to low temperatures across five generations, bypassing the genetic mutations that are central to Darwinism. The breakthrough reignites the 19th-century rivalry between French naturalist Jean-Baptiste Lamarck – whose 'giraffe theory' proposed that organisms can pass on learned survival traits – and Charles Darwin's ideas about random genetic variation. The research not only mirrored Lamarck's famed giraffe-neck parable, by pinpointing heritable DNA methylation changes as the driver of cold adaptation in crops, it also challenges modern biology to reconcile epigenetics with evolution's core principles. The team, led by researchers from the Chinese Academy of Sciences , showed that rice varieties from China's frosty northeast exhibited these stable, non-genetic adaptations – positioning Lamarckism as a potent, if partial, force in evolution's playbook. 'We demonstrate that environmentally induced epigenetic variation contributes to the inheritance of an acquired characteristic,' the team said, in a paper published in the peer-reviewed life sciences journal on May 22.
